TherapeuticsMD, Inc. (TXMD)
NASDAQ: TXMD · Real-Time Price · USD
1.080
-0.030 (-2.70%)
Sep 15, 2025, 4:00 PM EDT - Market closed
TherapeuticsMD Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 2.56 | 1.76 | 1.3 | 69.96 | 2.57 | 64.87 | Upgrade | |
Revenue Growth (YoY) | 156.93% | 35.25% | -98.14% | 2619.12% | -96.03% | 30.67% | Upgrade |
Cost of Revenue | - | - | - | 1.4 | 1.4 | 15.98 | Upgrade |
Gross Profit | 2.56 | 1.76 | 1.3 | 68.57 | 1.17 | 48.9 | Upgrade |
Selling, General & Admin | 4.45 | 4.74 | 8.9 | 56.71 | 72.75 | 192.87 | Upgrade |
Research & Development | - | - | - | - | - | 10.43 | Upgrade |
Operating Expenses | 4.83 | 5.25 | 9.83 | 57.9 | 72.75 | 203.31 | Upgrade |
Operating Income | -2.27 | -3.49 | -8.52 | 10.66 | -71.58 | -154.41 | Upgrade |
Interest Expense | - | - | - | - | - | -28.58 | Upgrade |
Interest & Investment Income | 0 | - | - | - | - | - | Upgrade |
Other Non Operating Income (Expenses) | 0.51 | 1.17 | 0.78 | -0.12 | 0.27 | 0.6 | Upgrade |
EBT Excluding Unusual Items | -1.76 | -2.33 | -7.74 | 10.55 | -71.31 | -182.39 | Upgrade |
Merger & Restructuring Charges | - | - | - | -9.47 | - | - | Upgrade |
Asset Writedown | -0.1 | -1.27 | - | - | - | -1.13 | Upgrade |
Other Unusual Items | 1.25 | 1.25 | - | - | -8 | - | Upgrade |
Pretax Income | -0.61 | -2.34 | -7.74 | 1.07 | -79.31 | -183.52 | Upgrade |
Income Tax Expense | -0.06 | -0.03 | -0.04 | - | - | - | Upgrade |
Earnings From Continuing Operations | -0.54 | -2.31 | -7.7 | 1.07 | -79.31 | -183.52 | Upgrade |
Earnings From Discontinued Operations | 0.09 | 0.13 | -2.58 | 110.92 | -93.11 | - | Upgrade |
Net Income | -0.46 | -2.18 | -10.28 | 112 | -172.42 | -183.52 | Upgrade |
Net Income to Common | -0.46 | -2.18 | -10.28 | 112 | -172.42 | -183.52 | Upgrade |
Shares Outstanding (Basic) | 12 | 12 | 10 | 9 | 8 | 6 | Upgrade |
Shares Outstanding (Diluted) | 12 | 12 | 10 | 9 | 8 | 6 | Upgrade |
Shares Change (YoY) | 2.98% | 10.45% | 11.48% | 17.66% | 44.39% | 11.89% | Upgrade |
EPS (Basic) | -0.04 | -0.19 | -0.98 | 12.41 | -21.66 | -33.29 | Upgrade |
EPS (Diluted) | -0.04 | -0.19 | -0.99 | 11.95 | -21.66 | -33.50 | Upgrade |
Free Cash Flow | 0.84 | 0.73 | -48.14 | -4.08 | -142.73 | -159.68 | Upgrade |
Free Cash Flow Per Share | 0.07 | 0.06 | -4.61 | -0.43 | -17.93 | -28.96 | Upgrade |
Gross Margin | 100.00% | 100.00% | 100.00% | 98.00% | 45.51% | 75.38% | Upgrade |
Operating Margin | -88.82% | -198.30% | -654.61% | 15.24% | -2781.85% | -238.02% | Upgrade |
Profit Margin | -17.94% | -123.85% | -789.40% | 160.08% | -6700.93% | -282.90% | Upgrade |
Free Cash Flow Margin | 32.71% | 41.57% | -3697.46% | -5.83% | -5547.10% | -246.14% | Upgrade |
EBITDA | -1.89 | -2.98 | -8.08 | 11.86 | -70.84 | -150.34 | Upgrade |
EBITDA Margin | -73.70% | -169.39% | - | 16.95% | - | -231.75% | Upgrade |
D&A For EBITDA | 0.39 | 0.51 | 0.44 | 1.19 | 0.74 | 4.07 | Upgrade |
EBIT | -2.27 | -3.49 | -8.52 | 10.66 | -71.58 | -154.41 | Upgrade |
EBIT Margin | -88.82% | -198.30% | - | 15.24% | - | -238.02% | Upgrade |
Revenue as Reported | - | - | - | 69.96 | 2.57 | 64.87 | Upgrade |
Advertising Expenses | - | - | - | - | - | 35.8 | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.